share_log

Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week

Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week

私營公司是湖南華納藥業有限公司, Ltd(上海證券交易所股票代碼:688799)的最大所有者在上週市值上漲4.27億元人民幣後獲得了回報
Simply Wall St ·  04/01 15:15

Key Insights

關鍵見解

  • Significant control over Hunan Warrant PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions
  • 56% of the business is held by the top 2 shareholders
  • Insider ownership in Hunan Warrant PharmaceuticalLtd is 19%
  • 私營公司對湖南華納德製藥有限公司的重大控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 56% 的業務由前兩名股東持有
  • 湖南華納德製藥有限公司的內部所有權爲19%

If you want to know who really controls Hunan Warrant Pharmaceutical Co.,Ltd (SHSE:688799), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 40% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正控制了湖南華納德製藥有限公司, Ltd(上海證券交易所代碼:688799),那麼你必須看看其股票登記處的構成。持有該公司股份最多的集團是私營公司,準確地說約爲40%。也就是說,如果股票上漲,該集團將受益最大(如果股價下跌,則損失最大)。

As a result, private companies were the biggest beneficiaries of last week's 9.7% gain.

結果,私營公司是上週9.7%漲幅的最大受益者。

In the chart below, we zoom in on the different ownership groups of Hunan Warrant PharmaceuticalLtd.

在下圖中,我們放大了湖南華納德製藥有限公司的不同所有權組。

ownership-breakdown
SHSE:688799 Ownership Breakdown April 1st 2024
SHSE: 688799 所有權明細 2024 年 4 月 1 日

What Does The Institutional Ownership Tell Us About Hunan Warrant PharmaceuticalLtd?

關於湖南華納德製藥有限公司,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

As you can see, institutional investors have a fair amount of stake in Hunan Warrant PharmaceuticalLtd. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Hunan Warrant PharmaceuticalLtd, (below). Of course, keep in mind that there are other factors to consider, too.

如你所見,機構投資者持有湖南華納德製藥有限公司的相當數量的股份。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎行事,不要依賴機構投資者所謂的驗證。他們也是,有時候會弄錯。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看湖南華納德製藥有限公司過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SHSE:688799 Earnings and Revenue Growth April 1st 2024
SHSE: 688799 2024 年 4 月 1 日收益和收入增長

We note that hedge funds don't have a meaningful investment in Hunan Warrant PharmaceuticalLtd. Our data shows that Hunan Warrant Pharmaceutical Investment Partnership Enterprise (Limited Partnership) is the largest shareholder with 40% of shares outstanding. For context, the second largest shareholder holds about 17% of the shares outstanding, followed by an ownership of 2.5% by the third-largest shareholder. Yan Jin, who is the third-largest shareholder, also happens to hold the title of Chairman of Corporate Board.

我們注意到,對沖基金沒有對湖南華納德製藥有限公司進行有意義的投資。我們的數據顯示,湖南華納德醫藥投資合夥企業(有限合夥)是最大股東,已發行股份的40%。就背景而言,第二大股東持有約17%的已發行股份,其次是第三大股東持有2.5%的所有權。第三大股東嚴進也恰好擁有公司董事會主席的頭銜。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前兩名股東擁有公司的多數股權,這意味着他們足夠強大,足以影響公司的決策。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。有一些分析師對這隻股票的報道,但隨着時間的推移,它仍可能變得更加廣爲人知。

Insider Ownership Of Hunan Warrant PharmaceuticalLtd

湖南華納德製藥有限公司的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our information suggests that insiders maintain a significant holding in Hunan Warrant Pharmaceutical Co.,Ltd. Insiders own CN¥927m worth of shares in the CN¥4.8b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我們的信息表明,內部人士持有湖南華納德製藥有限公司的大量股份。, Ltd. 內部人士擁有這家48億元人民幣公司價值9.27億元人民幣的股份。這可能表明創始人仍然擁有大量股份。你可以點擊這裏查看他們是否在買入或賣出。

General Public Ownership

一般公有制

With a 30% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Hunan Warrant PharmaceuticalLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

擁有30%所有權的公衆,主要由個人投資者組成,對湖南華德製藥有限公司有一定程度的影響力。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 40%, of the Hunan Warrant PharmaceuticalLtd stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

私人公司似乎擁有湖南沃瑞德製藥有限公司40%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 1 warning sign for Hunan Warrant PharmaceuticalLtd that you should be aware of before investing here.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們發現了湖南華瑞德製藥有限公司的一個警告信號,在這裏投資之前,你應該注意這個信號。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論